Dr. Klaus Lindpaintner Begins Serving as Vice President of R&D and CSO for Strategic Diagnostics

NEWARK, Del.--(BUSINESS WIRE)--

SDI (Strategic Diagnostics Inc., Nasdaq: SDIX), a provider of biotechnology-based products and services, today announced that Dr. Klaus Lindpaintner began serving as Vice President of Research & Development and Chief Scientific Officer (CSO) on February 1, 2010 as previously disclosed in its January 11, 2010 news release.

Prior to joining SDI, Dr. Lindpaintner was with F. Hoffmann-La Roche Ltd. and most recently served as Director of the “Roche Molecular Medicine Laboratories” at the company’s headquarters in Basel, Switzerland, and as Roche’s Global Head, Molecular Medicines Policy and External Affairs, coordinating the company’s efforts and activities in implementing biomarker research based on genetics, genomics, proteomics, and associated disciplines from early discovery to late-stage clinical trials. Dr. Lindpaintner graduated from the Innsbruck University Medical School with a degree in Medicine and from Harvard University with a degree in Public Health.

As part of Dr. Lindpaintner’s employment arrangements, he will receive a non-qualified option to purchase 75,000 shares of common stock at an exercise price of $1.50, as well as 25,000 shares of restricted stock, subject to the terms set forth in grant agreements to be dated as of February 1, 2010. Both the option and the restricted stock vest in four equal annual installments, beginning on the first anniversary of the date of grant.

About SDI

SDIX is a biotechnology company, expert at creating advantage by providing quality, innovative and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics and Food Safety markets.

For nearly 20 years, SDI has created antibodies that advance its customers’ immuno-based work – reducing time, labor and costs while increasing accuracy and reliability of results.

SDI offers a fully-integrated suite of immuno-solution capabilities, including its Genomic Antibody Technology ^TM (GAT) for diagnostic-grade clinical assays and research projects – from antibody candidate to critical high-quality reagent formulation. GAT enables fast and robust design and development of antibodies and antibody panels with high specificity, sensitivity and reliability. For more information, visit www.sdix.com.

This news release may contain forward-looking statements reflecting SDI's current expectations. When used in this press release, words like “anticipate,” “could,” “enable,” “estimate,” “intend,” “expect,” “believe,” “potential,” “will,” “should,” “project,” “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.